Observational studyClinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery2026
Laryngeal Cancer Survival in Northern United Kingdom: A Multi-Centre Retrospective Observational Study.
Observational study in Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Laryngeal Cancer Survival in Northern United Kingdom: A Multi-Centre Retrospective Observational Study.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLaryngeal cancer incidence has risen globally, yet survival outcomes have shown limited improvement over recent decades. This study evaluated contemporary outcomes across multiple centres in Northern UK and examined stage- and treatment-specific survival.
designMulti-centre retrospective observational study. SETTING AND
participantsData were collected for 2028 patients with biopsy-proven squamous cell carcinoma of the larynx treated with curative intent between 2015 and 2021 across six tertiary head and neck cancer centres (Newcastle, Glasgow, Liverpool, Sheffield, Leeds, and Middlesbrough).
main outcome measuresOverall survival (OS) and disease-specific survival (DSS) were estimated using Kaplan-Meier analysis and compared using log-rank testing.
resultsMedian follow-up was 40 months (mean age 66.8 years; 81% male). Overall mortality was 41% and disease-specific mortality 20%. Five-year OS declined with advancing stage: 72.0% (T1), 54.5% (T2), 50.6% (T3), and 45.2% (T4). In unadjusted analyses, surgery in T1 disease was associated with higher survival (5-year DSS 93.6% vs. 88.5%), while in advanced disease chemoradiotherapy was associated with the highest DSS (5-year DSS 70.2%), although differences were not statistically significant. No significant differences in DSS were observed across year of diagnosis (2015-2021).
conclusionsSurvival outcomes for laryngeal cancer remain poor and have shown limited improvement over time. These findings provide important real-world insights into contemporary outcomes and highlight the need for earlier detection, prevention strategies, and prospective collaborative research to improve future outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.